Differentiation of postsurgical or postradiation necrosis from tumor recurrence is a clinical dilemma. Magnetic resonance imaging does not always perform well in this setting. Several nuclear medicine techniques are available that offer a solution in such a clinical situation. We report a case where F-18 flurodeoxyglucose (FDG) and F-18 fluorothymidine (FLT) PET/ CT were used to identify recurrence of a glioma.
INTRODUCTION
Differentiating recurrent gliomas in a postoperative and postradiotherapy setting remains a challenge. Although magnetic resonance imaging (MRI) has superior sensitivity in lesion detection, its specificity is reported to be as low as 27%. 1 Several nuclear medicine techniques are available as a solution to this problem, e.g. Tc99m labeled glucoheptonate (GHA) or methoxyisobutylisonitrile (MIBI) SPECT, F-18 flurodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), F-18 fluorothymidine (FLT), F-18 F-DOPA and C-11 Methionine PET/CT.
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CASE REPORT
A 25-year-old female patient with a right temporal glioma underwent craniotomy and excision of the tumor in December 2010. Histopathology revealed a grade II astrocytoma. She presented 6 months later with vertigo, nausea and disorientation. Recurrence of tumor was suspected. The patient underwent F-18 FDG and F-18 FLT PET/CT studies. The FDG study revealed intense tracer uptake (SUVmax, 15.0) in the right temporal pole (Fig. 1A) , and the same focus was also demonstrated on the FLT PET/ CT (Fig. 1B) . However, apart from this lesion, the FDG PET/CT showed another focus of abnormal uptake in the periventricular region surrounding the anterior horn of the lateral ventricle on the left side (Fig. 1C) while the FLT PET/CT demonstrated increased tracer uptake in the 10.5005/jp-journals-10028-1046 periventricular regions on the lateral ventricles on both sides (Fig. 1D) . MRI showed a T2 hyperintense lesion in the right temporal lobe corresponding to the FDG avid focus (Figs 1E and F) . Contrast enhancing lesions were seen in bilateral periventricular-subependymal region and also involving the corpus callosum ( Figs 1G and H) . On the basis of the imaging findings, diagnosis of tumor recurrence with CSF spread was considered and the patient was scheduled for chemotherapy.
DISCUSSION
Although high-grade tumors show intense FDG uptake, the physiological uptake in the brain may interfere with accurate interpretation. Tracers like GHA, FLT, dihydroxyphenylalanine (DOPA) and methionine [2] [3] [4] [5] have an advantage in this respect as there is no physiological uptake of these tracers in the brain tissue. PET images have better resolution than SPECT images. FLT can therefore play a significant role in the detection of recurrences of gliomas. Several studies have reported the utility of F-18 FLT in predicting the grade of gliomas. [3] [4] [5] [6] [7] [8] Yamamoto et al in their study demonstrated significant correlation between metabolic volumes of recurrent glioblastoma multiforme and the volumes defined on MRI. 9 FLT was also better than methionine in tumor grading. 5 The uptake of this tracer in lesions is less than that of FDG. However, due to negligible uptake in the normal brain parenchyma, FLT provides a high tumor to background contrast that can help in detection of lesions.
The uptake of FLT in low-grade gliomas is expected to be low. 3 In the present case (a grade II astrocytoma), though the FDG uptake was very high (SUVmax, 15.0) but FLT showed definite abnormal uptake and identified the exact distribution of the recurrent lesions.
